Search Results

You are looking at 71 - 80 of 654 items for :

  • "immunotherapy" x
  • Refine by Access: All x
Clear All
Full access

CRE24-033: Complete Remission of Microsatellite Instability–High (MSI-H) Oligometastatic Poorly Differentiated Colon Adenocarcinoma After a Single Dose of Immunotherapy

Christine Jane Kurian and Danny Markabawi

impaired DNA mismatch repair proteins. 15% of all CRC is MSI-H, with 12% sporadic and 3% from hereditary non-polyposis CRC (HNPCC) or Lynch syndrome. First-line therapy for MSI-H metastatic colon adenocarcinoma is immunotherapy (FDA approval from the

Full access

HSR24-160: Immune Checkpoint Inhibitor-Induced Type 1 Diabetes Mellitus: Patient Characteristics, Clinical Outcomes, and Survival Implications of Autoantibodies

John Sharp, Cassandra Pasadyn, Songzhu Zhao, Lai Wei, Carolyn Presley, Dwight Owen, Kathleen Wyne, and Alexa Meara

-160: FIGURE 1. Overall survival from start of immunotherapy by presence of any T1D-associated autoantibody* at time of T1D diagnosis. *T1D-associated autoantibodies include anti-GAD, anti- pancreatic islet cell/ICA, anti-insulin/IAA, anti-IA2, and anti

Full access

The Role of Tissue Biopsy in the Management of Immune Checkpoint Inhibitor Toxicity

Leslie A. Fecher, Shrinivas Bishu, Robert J. Fontana, Salim S. Hayek, and Bryan J. Schneider

different, neutrophils are a feature of both, suggesting that FCP will also have high sensitivity and specificity in ICI-induced colitis. Figure 1. Recommended evaluation of patients with grade 1/2 diarrhea receiving immunotherapy. Abbreviations: EGD

Full access

HSR22-180: Real-World Treatment Patterns and Outcomes of Targeted Therapy and Immunotherapy in BRAF+ Cutaneous Melanoma Patients Treated in the Adjuvant Setting

Sanjay Chandrasekaran, You-Li Ling, Jackson Tang, Deborah Norton, and Rohan Shah

Background : Both immunotherapy (IO) and targeted therapy, specifically dabrafenib + trametinib (DT), are recommended by the NCCN guidelines for the management of BRAF+ cutaneous melanoma in the adjuvant setting. However, data surrounding their

Full access

CLO24-068: The Role of Obesity in Influencing Patient Survival in Metastatic Renal Cell Carcinoma Patients Receiving Immunotherapy: A Systematic Review and Meta-Analysis.

Chalothorn Wannaphut, Sakditad Saowapa, Natchaya Polpichai, Pharit Siladech, Manasawee Tanariyakul, Phuuwadith Wattanachayakul, and Pakin Lalitnithi

-analysis was to identify the relationship between obesity and the treatment outcome of metastatic renal cell carcinoma patients receiving immunotherapy. Research Design and Methodology PubMed, Cochrane Library, and Google Scholar databases were scoured for

Full access

CLO24-077: Role of Cytoreductive Nephrectomy in Metastatic Renal Cell Carcinoma in the Era of Immunotherapy: An Analysis of the National Cancer Database (NCDB)

Insija Ilyas Selene, Feitong Lei, Amina Dhahri, Jennifer C. Torres Yee, Bin Huang, Jemin Jose, and Zin Myint

Background: The landscape of metastatic renal cell carcinoma (mRCC) treatment has witnessed significant transformations with the emergence of immunotherapy-based combination regimens (IO-X), including IO-IO and IO-TKI. However, the role of

Full access

Prevalent Pseudoprogression and Pseudoresidue in Patients With Rectal Cancer Treated With Neoadjuvant Immune Checkpoint Inhibitors

Yumo Xie, Jinxin Lin, Ning Zhang, Xiaolin Wang, Puning Wang, Shaoyong Peng, Juan Li, Yuanhui Wu, Yaoyi Huang, Zhuokai Zhuang, Dingcheng Shen, Mingxuan Zhu, Xiaoxia Liu, Guangjian Liu, Xiaochun Meng, Meijin Huang, Huichuan Yu, and Yanxin Luo

program of the collaborating study group of tumor immunotherapy at the Sixth Affiliated Hospital of Sun Yat‐sen University. All patients provided written informed consent to receive nICIs in accordance with the Declaration of Helsinki. To compare nICIs

Full access

HSR22-124: Real-World Outcomes Among Patients With Stage IV Epidermal Growth Factor Receptor (EGFR) Mutated Non-Small Cell Lung Cancer Treated With EGFR Tyrosine Kinase Inhibitors Versus Immunotherapy With or Without Chemotherapy in First-line Setting

Jon Apple, Rahul Shenolikar, Kevin De Silva, Ping Sun, and Alexander Spira

aggressiveness of the tumor, physicians may initiate immunotherapy (IO) alone or in combination with chemotherapy (IO± chemo) or chemotherapy alone prior to receiving biomarker test results. Objective : To evaluate timing of 1L therapy in relation to biomarker

Full access

CLO24-080: Association Between Primary Tumor Size and Prognosis in De Novo Metastatic Renal Cell Carcinoma in Patients Who Underwent First Line Immunotherapy-Based Therapy: Real World Data Analysis

Insija Ilyas Selene, Roshmita Bardhan, Rani Jayswal, Amina Dhahri, Jennifer C. Torres Yee, Heidi L. Weiss, Kimberly D. Ratliff, and Zin Myint

Current treatment approaches for metastatic renal cell carcinoma (mRCC) are immunotherapy (IO) combinations such as (IO + IO) vs. (IO + tyrosine kinase inhibitor [TKI]) depending on IMDC risk factors, focusing on performance status and laboratory

Full access

Challenges of Toxicity Management in Immuno-Oncology

Stephanie Andrews

Adverse events (AEs) related to immunotherapies are, in general, easily managed, but occasionally can be fatal. Therefore, they should be evaluated promptly and managed appropriately and without delay, said Stephanie Andrews, MS, ANP-BC, Oncology